Global Liquid Biopsy Market Analysis Report 2023-2027: The Market has Moved Out of the Development Phase and Into the Growth Phase

Rhea-AI Summary

The newly released report by ResearchAndMarkets.com highlights the significant growth potential of the global Liquid Biopsy market from 2023 to 2027. The market has transitioned from development to growth, influenced by advancements in cancer diagnostics. The report analyzes market size forecasts by cancer type, usage, and geographic location. Key findings include the impact of COVID-19, technological innovations like Circulating Tumor Cells and Cell-Free DNA, and a detailed examination of market trends and players. Investors are encouraged to make informed decisions based on the latest data and projections concerning this evolving sector.

Positive

• Market has transitioned from development to growth phase.
• Detailed analysis includes forecasts by cancer type, usage, and region.
• Technological advancements in diagnostics signal potential market expansion.

Negative

• None.

DUBLIN, Feb. 9, 2023 /PRNewswire/ -- The "Liquid Biopsy Markets by Cancer, Usage, Biomarker, Place, & Product With Price and Volume Outlook. Including Executive and Consultant Guides and Customized Forecasting and Analysis 2023-2027" report has been added to  ResearchAndMarkets.com's offering.

 

The market is still in its infancy but has just moved out of the development phase and into the growth phase. The impact on the healthcare industry is enormous. The report forecasts the market size looking out 5 years. In addition, the report looks at potential market sizes by country, by cancer and by the four types of usage: screening, diagnosis, therapy selection and recurrence monitoring.

The Screening, Diagnostic, Therapy Selection, Minimal Residual Disease and Screening Market Potential are all explored in this report. What is the impact of the COVID pandemic on the Liquid Biopsy market? We look at Price and Volume Outlooks by type of cancer. This report provides detailed analysis.

Circulating Tumor Cells? Cell Free DNA? Exosomes? Find out about the technology in readily understood terms that explain the jargon. Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

A revolution in cancer diagnostics is occurring using in vitro blood testing to identify cancer DNA. The technology has created the possibility of widespread screening for all types of cancers with a blood test.

Illumina is now working on the Circulating Cell-Free Genome Atlas (CCGA) to help identify cancer early. Technology is moving faster than the market. New technology that definitively identifies disease conditions from blood samples is poised to replace expensive invasive surgical biopsy procedures.

The report includes detailed breakouts for 15 Countries and 4 Regions along with breakouts for Lung, Breast, Colorectal, Prostate, Cervical, and Other Cancers as well as breakouts by Screening/Early Detection, Diagnostic, Therapy Monitoring and Recurrence Monitoring.

Make investment decisions and valuations with confidence using the latest data.

Key Topics Covered:

1 Market Guides
1.1 Liquid Biopsy Market - Strategic Situation Analysis
1.2 Guide for Executives, Marketing, Sales and Business Development Staff
1.3 Guide for Management Consultants and Investment Advisors

2 Introduction and Market Definition
2.1 What is Liquid Biopsy?
2.2 The Sequencing Revolution
2.3 Market Definition
2.4 Methodology
2.5 Perspective: Healthcare and the IVD Industry
2.5.1 Global Healthcare Spending
2.5.2 Spending on Diagnostics
2.5.3 Important Role of Insurance for Diagnostics

3 Market Overview
3.1 Players in a Dynamic Market
3.1.1 Academic Research Lab
3.1.2 Diagnostic Test Developer
3.1.3 Instrumentation Supplier
3.1.4 Chemical/Reagent Supplier
3.1.5 Pathology Supplier
3.1.6 Independent Clinical Laboratory
3.1.7 Public National/regional Laboratory
3.1.8 Hospital Laboratory
3.1.9 Physicians Office Lab (POLS)
3.1.10 Audit Body
3.1.11 Certification Body
3.2 Using Biopsies
3.2.1 Cancer
3.2.2 Precancerous conditions
3.2.3 Inflammatory conditions
3.3 Biopsy Sites
3.4 The Situation Today - Biopsy Analysis
3.5 Evidence of Cancer - Liquid Biopsy Technology
3.5.1 The Big Picture on Liquid Biopsy Technology
3.5.2 The Role of CTCs
3.5.3 Application of CTCs
3.5.4 CellSearch Detection- Ultimate Sensitivity
3.5.5 Epic Sciences Detection- Imaging Takes the Lead
3.5.6 Maintrac Detection - The Microscope
3.5.7 Other Methods
3.5.8 ctDNA Role
3.5.9 ctDNA Applications
3.5.10 Exosomes and Micro Vesicles - New Kid on the Block
3.5.11 The Multiple Play
3.6 Cancer Treatment Protocol Under Siege
3.6.1 Issues to Liquid Biopsy Adoption - Double Diagnostics
3.6.2 The Cancer Screening Market Opportunity
3.6.2.1 GRAIL - What Is It?
3.6.3 Cancer Management vs. Diagnosis
3.6.3.1 The Role of Risk Assessment
3.6.3.2 Managing Therapy
3.6.3.3 Monitoring Disease - What Is It?
3.6.4 Phases of Adoption - Looking into The Future
3.6.5 The Promise of Liquid Biopsy
3.7 Structure of Industry Plays a Part
3.7.1 Hospital Testing Share
3.7.2 Economies of Scale
3.7.2.1 Hospital vs. Central Lab
3.7.3 Physician Office Lab's
3.7.4 Physician's and POCT

4 Market Trends
4.1 Factors Driving Growth
4.1.1 Non-Invasive Game Changer
4.1.2 Lower Cost
4.1.3 Greater Accuracy
4.1.4 Wide Range of Potential Uses
4.1.5 Aging Population
4.2 Factors Limiting Growth
4.2.1 Lower prices
4.2.2 Lack of Standards
4.2.3 Protocol Resistance
4.2.4 Initial Adoption Cost
4.2.5 Conclusion
4.3 Instrumentation and Automation
4.3.1 Instruments Key to Market Share
4.3.2 Bioinformatics Plays a Role
4.4 Diagnostic Technology Development
4.4.1 Next Generation Sequencing Fuels a Revolution
4.4.2 Impact of NGS on pricing
4.4.3 Pharmacogenomics Blurs Diagnosis and Treatment
4.4.4 CGES Testing, A Brave New World
4.4.5 Biochips/Giant magneto resistance based assay

5. Liquid Biopsy Recent Developments
5.1. Recent Developments - Importance and How to Use This Section
5.1.1. Importance of These Developments
5.1.2. How to Use This Section
5.2. Sophia Genetics to Commercialize Liquid Biopsy Test
5.3. Agilent, Qiagen Nab FDA Approvals for Lung Cancer Treatment CDx
5.4. Liquid Biopsy Startup Haystack Oncology Raises $56M
5.5. Hedera Dx to Launch Liquid Biopsy Streamlined Platform
5.6. PamGene Expanding Liquid Biopsy Assays
5.7. Liquid Biopsy Firm Hedera Dx Raises €14M
5.8. MDxHealth Plans One-Stop Shop for Prostate Cancer Dx
5.9. Precision Oncology Dx Access Varies Widely in Europe
5.10. Extracellular Vesicles Show Promise as Early-Stage Cancer Diagnostic
5.11. Predicine Receives CE Mark for Blood and Urine Liquid Biopsy
5.12. BillionToOne Launches First Liquid Biopsy Products
5.13. Dxcover Advances Multicancer Detection Platform
5.14. CorePath Laboratories, Cizzle Biotechnology Partner on Lung Cancer Blood Test
5.15. Illumina Sues Guardant Health Over Patents
5.16. Invitae to Expand Cancer Testing Portfolio
5.17. Cancer Centre, Inivata Partner on Clinical Liquid Biopsy Studies
5.18. IVBH Bio Takes Aim at With Liquid Biopsy Incubator
5.19. Molecular Health, Eone-Diagnomics Ink Liquid Biopsy Partnership
5.20. Delfi Diagnostics Looks To Fragmentation-Based Liquid Biopsy Tech
5.21. BillionToOne Adapting Fetal Dx Tech for Liquid Biopsy
5.22. EDGC to Expand Liquid Biopsy Space With Cell-Free DNA Platform
5.23. Liquid Biopsy Startup BioCaptiva Raises £1M in Seed Funding
5.24. Agilent Enters Liquid Biopsy Market with Resolution Biosciences Acquisition
5.25. Bio-Techne to Acquire Asuragen for up to $320M
5.26. Personalis Broadens Liquid Biopsy Offering
5.27. Exact Sciences to Offer End-to-End Cancer Testing With Ashion Acquisition
5.28. Delfi Diagnostics Plans Multi-Cancer Screening Test
5.29. Menarini's CellSearch Shows Potential to Predict Breast Cancer Prognosis, Treatment Response
5.30. Liquid Biopsy NGS Panels-Diverse Test Claims
5.31. CMS Colon Cancer Screening Memo Bodes Well for Assays
5.32. Natera Liquid Biopsy Test Coverage to Expand
5.33. Freenome Closes Financing to Support Early Cancer Detection Trial
5.34. C$2.6M Liquid Biopsy Initiative
5.35. NeoGenomics, Inivata Partner for Lung Cancer Liquid Biopsy
5.36. Liquid Biopsy Shows Promise as Screen for Cancers
5.37. Inivata launches RaDaRT for the detection of residual disease and recurrence
5.38. Liquid Biopsy Assay Detects 50+ Types of Cancer
5.39. Liquid Biopsy Study Confirms Concordance with Tissue Biopsy

6. Profiles of Key Players
6.1. Abbott Laboratories
6.2. AccuraGen Inc.
6.3. Acuamark Diagnostics
6.4. Admera Health, LLC
6.5. Agilent/Dako
6.6. Amoy Diagnostics Co., Ltd.
6.7. Anchor Dx
6.8. ANGLE plc
6.9. Applied DNA Sciences
6.10. ARUP Laboratories
6.11. AVIVA Systems Biology
6.12. Baylor Miraca Genetics Laboratories
6.13. Beckman Coulter Diagnostics
6.14. Becton, Dickinson and Company
6.15. BGI Genomics Co. Ltd
6.16. Bioarray Genetics
6.17. Biocartis
6.18. Biocept, Inc.
6.19. Biodesix Inc.
6.20. BioFluidica
6.21. bioMerieux Diagnostics
6.22. Bioneer Corporation
6.23. Bio-Rad Laboratories, Inc
6.24. Bio-Techne
6.25. Bioview
6.26. Bolidics
6.27. Boreal Genomics
6.28. Burning Rock
6.29. Cardiff Oncology
6.30. Caris Molecular Diagnostics
6.31. CellCarta
6.32. CellMax Life
6.33. Cepheid (Danaher)
6.34. Circulogene
6.35. Cizzle Biotech
6.36. Clinical Genomics
6.37. Cytolumina Technologies Corp.
6.38. Datar Cancer Genetics Limited
6.39. Diagnologix LLC
6.40. Dxcover
6.41. Enzo Biochem
6.42. Epic Sciences
6.43. Epigenomics AG
6.44. Eurofins Scientific
6.45. Exact Sciences
6.46. Fluxion Biosciences
6.47. Freenome
6.48. Fyr Diagnostics
6.49. GeneFirst Ltd.
6.50. Genetron Holdings
6.51. GILUPI Nanomedizin
6.52. Guardant Health
6.53. HansaBiomed
6.54. Haystack Oncology
6.55. HeiScreen
6.56. Helomics
6.57. iCellate
6.58. ICON PLC
6.59. Illumina
6.60. Incell Dx
6.61. Inivata
6.62. INOVIQ
6.63. Integrated Diagnostics
6.64. Invitae Corporation
6.65. Janssen Diagnostics
6.66. Lunglife AI Inc
6.67. MDNA Life SCIENCES, Inc.
6.68. MDx Health
6.69. Menarini Silicon Biosystems
6.70. Mesa Laboratories, Inc.
6.71. Millipore Sigma
6.72. Miltenyi Biotec
6.73. miR Scientific
6.74. Myriad Genetics/Myriad RBM
6.75. NantHealth, Inc.
6.76. Natera
6.77. NeoGenomics
6.78. Novogene Bioinformatics Technology Co., Ltd.
6.79. On-Chip Biotechnologies
6.80. Oncocyte
6.81. OncoDNA
6.82. Oxford Nanopore Technologies
6.83. PamGene
6.84. Panagene
6.85. Perkin Elmer
6.86. Personal Genome Diagnostics
6.87. Precision Medicine Group
6.88. PrecisionMed
6.89. Predicine
6.90. Promega
6.91. Qiagen
6.92. Rarecells SAS
6.93. RareCyte
6.94. Roche Molecular Diagnostics
6.95. Screencell
6.96. Siemens Healthineers
6.97. simfo GmbH
6.98. Singlera Genomics Inc.
6.99. Standard BioTools
6.100. Sysmex Inostics
6.101. Tempus Labs, Inc.
6.102. Thermo Fisher Scientific Inc.
6.103. Todos Medical
6.104. Veracyte
6.105. Volition
6.106. Vortex Biosciences

For more information about this report visit https://www.researchandmarkets.com/r/fqhsp8-biopsy?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact: Laura Wood | +353-1-481-1716 | press@researchandmarkets.net

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/global-liquid-biopsy-market-analysis-report-2023-2027-the-market-has-moved-out-of-the-development-phase-and-into-the-growth-phase-301742388.html

SOURCE Research and Markets

FAQ

What does the latest report say about the Liquid Biopsy market growth?

The report indicates that the Liquid Biopsy market is moving from development into a growth phase, reflecting significant industry advancements.

How does COVID-19 impact the Liquid Biopsy market according to the report?

The report discusses the impact of COVID-19 on the Liquid Biopsy market, specifically within the context of screening and diagnostic processes.

What are the key technologies mentioned in the Liquid Biopsy market report?

The report highlights technologies like Circulating Tumor Cells and Cell-Free DNA as key innovations shaping the Liquid Biopsy market.

Which cancer types are analyzed in the Liquid Biopsy market report?

The report examines various cancer types including lung, breast, colorectal, and prostate cancers, among others.

How is the Liquid Biopsy market projected to evolve by 2027?

The report provides forecasts suggesting considerable market growth and increased adoption of Liquid Biopsy technologies by 2027.